-
Merck traditionally has been a leader in vaccines but has not had success with a COVID-19 vaccine. It's lending a hand to Johnson & Johnson, where production is running significantly behind schedule.
-
Johnson & Johnson has started shipping its first vaccine doses across the U.S., adding a third vaccine to the country's arsenal as public health officials warn of an uptick in cases.
-
The vaccine did better at preventing disease in the U.S. – 72% — and less well in South Africa – 57% efficacy. The efficacy seen in Latin America was 66%.
-
The move by Eli Lilly came less than 24 hours after Johnson & Johnson paused further dosing in all of its COVID-19 vaccine candidate clinical trials while it investigated a volunteer's illness.
-
The company says demand has declined "fueled by misinformation around the safety of the product and a constant barrage of litigation advertising." Lawsuits allege that the powder causes cancer.
-
The new number from Judge Thad Balkman comes nearly three months after he ordered the drugmaker to pay $572 million for its role in the opioid crisis. Both sides had questioned that sum.
-
The agreement removes the drugmaker from the list of defendants in an upcoming federal opioid trial and follows an August settlement in Oklahoma in which it agreed to pay $572 million.